
Assessed for eligibility (n=122)
Excluded (n=19)
-Not meeting inclusion criteria (n=17)
-Declined to participate (n=2)
Randomly assigned (n=103)
Allocation
Allocated to Control treatment (n=31)
-Received allocated intervention (n=31)
Allocated to EPA treatment (n=20)
-Received allocated intervention (n=20)
Allocated to α-lipoic acid treatment (n=26)
-Received allocated intervention (n=23)
-Did not receive allocated intervention (did not come to first visit n= 3)
Allocated to EPA+α-lipoic acid treatment (n=26)
-Received allocated intervention (n=23)
-Did not receive allocated intervention (did not come to first visit n = 3)
Follow-up
-Lost to follow-up (n=7)
-Discontinued intervention (health problem n=1, time incompatibilities n=1)
-Lost to follow-up (n=1)
-Discontinued intervention (health problem n=1)
-Lost to follow-up (n=2)
-Discontinued intervention (health problem n=1)
-Lost to follow-up (n=4)
-Discontinued intervention (viral infection n=1, did not follow assigned treatment n=1)
Analysis
Analyzed-primary outcome (n=22)
Analyzed-biochemical variables (n=21)
-Excluded from analysis (problems with blood collection n=1)
Analyzed-OGTT (n=19)
-Excluded from analysis (incomplete data n=3)
Analyzed-primary outcome (n=18)
Analyzed-biochemical variables (n=16)
-Excluded from analysis (problems with blood collection n=2)
Analyzed-OGTT (n=15)
-Excluded from analysis (incomplete data n=3)
Analyzed-primary outcome (n=20)
Analyzed-biochemical variables (n=19)
-Excluded from analysis (problems with blood collection n=1)
Analyzed-OGTT (n=18)
-Excluded from analysis (incomplete data n=2)
Analyzed-primary outcome (n=17)
Analyzed-biochemical variables (n=17)
Analyzed-OGTT (n=16)
-Excluded from analysis (incomplete data n=1)